Advocacy intelligence hub — real-time data for patient organizations
Zenapax: FDA approved
Prophylaxis of acute organ rejection in patients receiving renal transplants, to be used as a part of an immunosuppressive regimen that includes cyclosporine and corticosteroids.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Zenapax
Hoffmann-La Roche, Inc.
Zenapax
(Daclizumab)Orphan drugHoffmann-La Roche, Inc.
Alejandro Berenstein, M.D
St. Luke's-Roosevelt Hospital Center
Darren Orbach, MD PhD, M.D
Boston Children's Hospital
📍 BOSTON, MA
Denis Schmartz, MD
Brugmann University Hospital & HUDERF
Ahmed Otokiti, MBBS, MD
St. Luke's-Roosevelt Hospital Center
📍 OSHKOSH, WI
Shivani D Rangwala, M.D
Boston Children's Hospital
📍 BOSTON, MA
Tomoyoshi Shigematsu, M.D., Ph.D
Mount Sinai Hospital
📍 NEW YORK, NY